Polygala extract for the treatment of attention-deficit hyperactivity disorder
US11857592B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2020 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Aug 25, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/333
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a method of treating Attention-Deficit Hyperactivity Disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (such as PDC-1421). A solid dosage form of the composition can be prepared into the gelatin capsule. The oral administration of the composition in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extract.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.